107 related articles for article (PubMed ID: 23250957)
1. Overcoming resistance to MAPK pathway inhibitors.
Davies MA; Kopetz S
J Natl Cancer Inst; 2013 Jan; 105(1):9-10. PubMed ID: 23250957
[No Abstract] [Full Text] [Related]
2. Effect of SMURF2 targeting on susceptibility to MEK inhibitors in melanoma.
Smith MP; Ferguson J; Arozarena I; Hayward R; Marais R; Chapman A; Hurlstone A; Wellbrock C
J Natl Cancer Inst; 2013 Jan; 105(1):33-46. PubMed ID: 23250956
[TBL] [Abstract][Full Text] [Related]
3. Targeting MAPK pathway in melanoma therapy.
Cheng Y; Zhang G; Li G
Cancer Metastasis Rev; 2013 Dec; 32(3-4):567-84. PubMed ID: 23584575
[TBL] [Abstract][Full Text] [Related]
4. Mechanisms and strategies to overcome resistance to molecularly targeted therapy for melanoma.
Lim SY; Menzies AM; Rizos H
Cancer; 2017 Jun; 123(S11):2118-2129. PubMed ID: 28543695
[TBL] [Abstract][Full Text] [Related]
5. Pharmacologic mitogen-activated protein/extracellular signal-regulated kinase kinase/mitogen-activated protein kinase inhibitors interact synergistically with STI571 to induce apoptosis in Bcr/Abl-expressing human leukemia cells.
Yu C; Krystal G; Varticovksi L; McKinstry R; Rahmani M; Dent P; Grant S
Cancer Res; 2002 Jan; 62(1):188-99. PubMed ID: 11782377
[TBL] [Abstract][Full Text] [Related]
6. The mitogen-activated protein kinase pathway in melanoma part I - Activation and primary resistance mechanisms to BRAF inhibition.
Amaral T; Sinnberg T; Meier F; Krepler C; Levesque M; Niessner H; Garbe C
Eur J Cancer; 2017 Mar; 73():85-92. PubMed ID: 28169047
[TBL] [Abstract][Full Text] [Related]
7. Small Molecule Drugs and Targeted Therapy for Melanoma: Current Strategies and Future Directions.
Cerchia C; Lavecchia A
Curr Med Chem; 2017; 24(21):2312-2344. PubMed ID: 28413965
[TBL] [Abstract][Full Text] [Related]
8. Upstream mitogen-activated protein kinase (MAPK) pathway inhibition: MEK inhibitor followed by a BRAF inhibitor in advanced melanoma patients.
Goldinger SM; Zimmer L; Schulz C; Ugurel S; Hoeller C; Kaehler KC; Schadendorf D; Hassel JC; Becker J; Hauschild A; Dummer R;
Eur J Cancer; 2014 Jan; 50(2):406-10. PubMed ID: 24183461
[TBL] [Abstract][Full Text] [Related]
9. Cyclin-dependent kinases as therapeutic targets in melanoma.
Miller DM; Flaherty KT
Pigment Cell Melanoma Res; 2014 May; 27(3):351-65. PubMed ID: 24405945
[TBL] [Abstract][Full Text] [Related]
10. Targeting the mitogen-activated protein kinase pathway in the treatment of malignant melanoma.
Panka DJ; Atkins MB; Mier JW
Clin Cancer Res; 2006 Apr; 12(7 Pt 2):2371s-2375s. PubMed ID: 16609061
[TBL] [Abstract][Full Text] [Related]
11. Molecular targeted therapy for patients with melanoma: the promise of MAPK pathway inhibition and beyond.
Sullivan RJ; Atkins MB
Expert Opin Investig Drugs; 2010 Oct; 19(10):1205-16. PubMed ID: 20687784
[TBL] [Abstract][Full Text] [Related]
12. E3 ubiquitin ligases as drug targets and prognostic biomarkers in melanoma.
Bielskienė K; Bagdonienė L; Mozūraitienė J; Kazbarienė B; Janulionis E
Medicina (Kaunas); 2015; 51(1):1-9. PubMed ID: 25744769
[TBL] [Abstract][Full Text] [Related]
13. Treatment of metastatic melanoma with an orally available inhibitor of the Ras-Raf-MAPK cascade.
Collisson EA; De A; Suzuki H; Gambhir SS; Kolodney MS
Cancer Res; 2003 Sep; 63(18):5669-73. PubMed ID: 14522881
[TBL] [Abstract][Full Text] [Related]
14. Resistance to combination BRAF and MEK inhibition in metastatic melanoma: Where to next?
Welsh SJ; Rizos H; Scolyer RA; Long GV
Eur J Cancer; 2016 Jul; 62():76-85. PubMed ID: 27232329
[TBL] [Abstract][Full Text] [Related]
15. Targeting RAS/RAF/MEK/ERK signaling in metastatic melanoma.
Wang AX; Qi XY
IUBMB Life; 2013 Sep; 65(9):748-58. PubMed ID: 23893853
[TBL] [Abstract][Full Text] [Related]
16. Human melanoma cells resistant to MAPK inhibitors can be effectively targeted by inhibition of the p90 ribosomal S6 kinase.
Kosnopfel C; Sinnberg T; Sauer B; Niessner H; Schmitt A; Makino E; Forschner A; Hailfinger S; Garbe C; Schittek B
Oncotarget; 2017 May; 8(22):35761-35775. PubMed ID: 28415756
[TBL] [Abstract][Full Text] [Related]
17. A novel BH3 mimetic reveals a mitogen-activated protein kinase-dependent mechanism of melanoma cell death controlled by p53 and reactive oxygen species.
Verhaegen M; Bauer JA; Martín de la Vega C; Wang G; Wolter KG; Brenner JC; Nikolovska-Coleska Z; Bengtson A; Nair R; Elder JT; Van Brocklin M; Carey TE; Bradford CR; Wang S; Soengas MS
Cancer Res; 2006 Dec; 66(23):11348-59. PubMed ID: 17145881
[TBL] [Abstract][Full Text] [Related]
18. Mitogen-activated protein kinase (MEK) inhibitors to treat melanoma alone or in combination with other kinase inhibitors.
Faghfuri E; Nikfar S; Niaz K; Faramarzi MA; Abdollahi M
Expert Opin Drug Metab Toxicol; 2018 Mar; 14(3):317-330. PubMed ID: 29363351
[TBL] [Abstract][Full Text] [Related]
19. Binimetinib for the treatment of NRAS-mutant melanoma.
Queirolo P; Spagnolo F
Expert Rev Anticancer Ther; 2017 Nov; 17(11):985-990. PubMed ID: 28851243
[TBL] [Abstract][Full Text] [Related]
20. Immune Responses to BRAF-Targeted Therapy in Melanoma: Is Targeted Therapy Immunotherapy?
Kelley MC
Crit Rev Oncog; 2016; 21(1-2):83-91. PubMed ID: 27481005
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
